Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vasopressin receptor antagonists.

A Greenberg1, J G Verbalis

  • 1Department of Medicine, Division of Nephrology, Duke University Medical Center, Durham, North Carolina 27710, USA. arthur.greenberg@duke.edu

Kidney International
|May 5, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topical intra articular tranexamic acid reduces packed blood cell consumption in total joint arthroplasty.

Acta ortopedica mexicana·2026
Same author

The Gantzer transfer - Assessment of the feasibility of using the nerve supplying the Gantzer muscle for end-to-side supercharging of the ulnar nerve.

Hand surgery & rehabilitation·2022
Same author

Reflections on the Physics of Compton Scatter.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same author

The distribution of heat in bone during radiofrequency ablation of an ex vivo bovine model of osteoid osteoma.

The bone & joint journal·2014
Same author

Exploring data quality for some inorganic and organic constituents of inhalable particulate matter (PM10).

Environmental monitoring and assessment·2013
Same author

HLA antibody-incompatible kidney transplantation between jehovah's witnesses--a case report.

Transplantation proceedings·2013

New non-peptide vasopressin receptor antagonists (VRAs) effectively treat hyponatremia by reducing urine concentration and increasing sodium levels. Further research is needed for optimal use in severe cases and long-term benefits.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • The first non-peptide vasopressin receptor antagonist (VRA) is now FDA-approved, with others in late-stage development.
  • These agents target vasopressin V2 receptors, influencing water balance and sodium regulation.

Purpose of the Study:

  • To review the efficacy and safety of non-peptide VRAs in treating hyponatremia.
  • To discuss the potential role of VRAs in managing congestive heart failure and polycystic kidney disease.

Main Methods:

  • Analysis of Phase 3 clinical trial data for non-peptide VRAs.
  • Review of current literature on VRA pharmacology and clinical applications.

Main Results:

  • VRAs predictably reduce urine osmolality and increase electrolyte-free water excretion.

Related Experiment Videos

  • These agents effectively raise serum sodium concentration in euvolemic and hypervolemic hyponatremia.
  • Increased thirst is a noted side effect, and water restriction may still be necessary.

    • Conclusions:

    • Non-peptide VRAs are poised to become a primary treatment for hyponatremia.
    • Further studies are required to establish optimal use in acute, severe hyponatremia and assess long-term outcomes.
    • Long-term benefits in heart failure and kidney disease require further investigation.